Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
Patents for C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
05/2005
05/26/2005WO2005047249A1 Benzylether amine compounds useful as ccr-5 antagonists
05/26/2005WO2005047244A2 Inhibition of fgfr3 and treatment of multiple myeloma
05/26/2005WO2005047242A2 Compounds containing thiosulfate moieties
05/26/2005WO2005046674A2 Antibacterial compositions
05/26/2005WO2005046590A2 Methods for synthesizing quinolinone compounds
05/26/2005WO2005046589A2 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
05/26/2005WO2005046588A2 Compounds, compositions, and methods
05/26/2005WO2005007642A3 Novel azaheterocyclic amides useful for treating pain
05/26/2005WO2004112719A8 Chemical compounds
05/26/2005US20050113576 especially isoquinolines 5-substituted with urea, carboxamide or carbamate groups, e.g., N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; useful for treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity
05/26/2005US20050113554 Hyperbranched polymers
05/26/2005US20050113520 used in optical telecommunications devices such as waveguides; monomers such as 2,4,6-tris(4-ethenyl-2,3,5,6-tetrafluorophenyl)-1,3,5-triazine
05/26/2005US20050113392 6,7-dihydro-5H-pyrazolo(1,2-a)pyrazol-1-ones
05/26/2005US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
05/26/2005US20050113380 [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists
05/26/2005US20050113379 Corticotropin releasing factor (CRF); affective disorders, anxiety disorders, stress-related disorders, eating disorders and substance abuse; eg 5-(1-Ethyl-propyl)-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3,7-dimethyl-5H-pyrrolo[2,3-b]pyrazine
05/26/2005US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors
05/26/2005US20050113375 Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
05/26/2005US20050113373 medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample
05/26/2005US20050113366 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses
05/26/2005US20050113361 Amide derivatives as NMDA receptor antagonists
05/26/2005US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one
05/26/2005US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone
05/26/2005US20050113357 Cholinergic agents such as 3-[3-(4-methoxypiperidine)-1-yl-propyl]-1H-indole; for therapy of cognitive dysfunction, forgetfulness, confusion, memory loss, attention deficits, deficits in visual perception, depression, pain, sleep disorders, and psychosis
05/26/2005US20050113341 Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis
05/26/2005US20050113340 9-(Substituted aryl, heteroaryl, alicyclyl, or heterocyclyl)methyl-2-amino-6-halopurines, e.g., 6-chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine; used in the treatment and prevention of various Heat Shock Protein 90 mediated disorders, e.g., proliferative disorders
05/26/2005US20050113339 inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorder, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, and malignant disease
05/26/2005US20050112703 Detect signal generated by phosphorescence labels; reducing background interference
05/26/2005US20050112693 Screening, biosynthesis of peptides
05/26/2005US20050112487 electroconductive supports having layers containing azo compounds, charge transporting substance, acceptors and phenolic compounds, used in laser printer as well as high speed copiers
05/26/2005CA2545781A1 Bicyclic pyrazolone cytokine inhibitors
05/26/2005CA2544492A1 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
05/26/2005CA2544186A1 Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones
05/26/2005CA2543913A1 Benzylether amine compounds useful as ccr-5 antagonists
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1533312A1 Hetero-bicyclic compounds
05/25/2005EP1532210A1 Rylene dyes
05/25/2005EP1532209A2 Charge transport compositions and electronic devices made with such compositions
05/25/2005EP1532159A2 Scaffolded maleimide clusters for multivalent peptide assembly
05/25/2005EP1532153A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents
05/25/2005EP1532152A1 Novel polymorph of n-methyl-n-(3- 3- 2-thienylcarbonyl]-pyrazol- 1,5-alpha]-pyrimidin-7-yl phenyl)acetamide and compositions and methods related thereto
05/25/2005EP1532148A1 Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity
05/25/2005EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
05/25/2005EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
05/25/2005EP1531820A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases
05/25/2005EP1531811A2 Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
05/25/2005EP1140814B1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
05/25/2005EP0904274B1 Farnesyl transferase inhibitors
05/25/2005EP0836613B1 Water-soluble adenosine kinase inhibitors
05/25/2005DE10349672A1 New pyrazinopyrimidine or pyrazinoimidazole derivatives useful for weight reduction in mammals, for preventing or treating obesity, type II diabetes or metabolic syndrome and for treating sexual disorders
05/25/2005CN1620454A Amyloid plaque aggregation inhibitors and diagnostic imaging agents
05/25/2005CN1620452A 3, 4-dihydro-1h-isoquinoloin-2-yl-derivatives
05/25/2005CN1620451A Benzhydryl derivatives
05/25/2005CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use
05/25/2005CN1620289A Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy
05/25/2005CN1203089C New compound
05/25/2005CN1203073C Novel process for producing fused imidazopridine derivative and crystal form
05/24/2005US6897321 Process for preparing azacycloalkanoylaminothiazoles (LD 137e)
05/24/2005US6897311 Cycloamidation and subsequent reduction of an octahydrotetraaza-acenaphthylene isomer; intermediates for chelate compounds
05/24/2005US6897225 Inhibitors of αLβ2 mediated cell adhesion
05/24/2005US6897220 Antiproliferative agents
05/24/2005US6897217 Central nervous system diosrders; Parkinson's disease; sedatives, antixiolytic agents, antiepileptic agents
05/24/2005US6897216 Adenosine A2a receptor antagonists
05/24/2005US6897215 6-(6,5-Bicyclopiperazinyl)-1-(1- naphthylenesulphonyl)indole, for treating schizophrenia, depression, cognition and memory dysfunction, attention deficit disorder
05/24/2005US6897208 Protein kinase inhibitors
05/24/2005US6897207 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors
05/24/2005CA2210708C Tricyclic vasopressin antagonists
05/24/2005CA2195615C A process for the manufacture of imidazodiazepine derivatives
05/19/2005WO2005044822A1 Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
05/19/2005WO2005044819A1 Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
05/19/2005WO2005044791A2 2-halogen-6-alkyl-phenyl-substituted tetramic acid derivatives
05/19/2005WO2005044308A1 Phosphonate analogs of antimetabolites
05/19/2005WO2004106492A3 Bicyclicpyrimidones and their use to treat diseases
05/19/2005WO2004097406A3 Nϵ AND/OR Nα DERIVATIZED, METAL AND ORGANIC PROTECTED L-HISTIDINE FOR COUPLING TO BIOMOLECULES FOR HIGHLY EFFICIENT LABELING WITH [M(OH2)3(CO)3]+ BY FAC COORDINATION
05/19/2005WO2004075846A3 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
05/19/2005WO2003049678A3 Mitotic kinesin inhibitors
05/19/2005US20050107611 For use as adenosine receptor ligands; immunostimulants; contraceptives
05/19/2005US20050107604 Reagent for determining the absolute configuration of chiral compound and determination method
05/19/2005US20050107462 Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
05/19/2005US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors
05/19/2005US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders
05/19/2005US20050107419 E.g., Ethyl 2-[2-(4-fluorophenyl)ethyl]-4-(4-{[(2-furylmethyl)amino]carbonyl}phenyl)-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylate; analogous compounds based on the 7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine ring; osteoporous; bone disorders; osteoarthritis
05/19/2005US20050107412 Pharmaceutically active compounds
05/19/2005US20050107404 Mitotic kinesin inhibitors
05/19/2005US20050107394 Novel use of selective pde5 inhibitors
05/19/2005US20050107391 E.g., 4-(6-Thiophen-2-yl-imidazo[4,5-b]pyrazin-1-ylmethyl)-phenol and 6-Bromo-1-(4-fluoro-benzyl)-1H-[1,2,3]triazolo[4,5-b]pyrazine; treating lung cancer, and renal cancer
05/19/2005US20050107390 i.e. 7-[(3R)-3-Amino-4-(3,4-difluorophenyl)butanoyl]-3-methyl-6-(phenylmethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine, dihydrochloride; antilipemic, antiobesity
05/19/2005US20050107365 adrenoceptor or G-protein coupled receptors inhibitors such as 3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-2H-benzo[1,2,4]-thiadiazine-1,1-dioxide and carriers, used for prophylaxis of urogenital disorders, or as analgesics
05/19/2005US20050107343 Pyrrolo[2,3-d]pyrimidin-2-ylamines substituted in the 7th position by a aryl, heteroaryl, alicyclic, or heterocyclic group connected by methyl, C(O) , C(S) , S(O) or SO2; used in the treatment and prevention of various Heat Shock Protein 90 mediated disorders, e.g., proliferative disorders
05/19/2005US20050107321 FLK-1 is a receptor for vascular endothelial growth factor
05/19/2005DE10348023A1 Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen New alanyl aminopeptidase inhibitors for functional interference of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
05/19/2005CA2544752A1 Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
05/19/2005CA2544548A1 2-halogen-6-alkyl-phenyl-substituted tetramic acid derivatives
05/18/2005EP1530574A1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments
05/18/2005EP1530573A1 Condensed heterocyclic pyrazole derivatives as kinase inhibitors
05/18/2005EP1530572A2 Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
05/18/2005EP1530566A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
05/18/2005CN1617873A Aluminium and hexa methylene tetramine composite and application thereof
05/18/2005CN1617872A Non crystalline tricyclic triazolobenzazepine derivative
05/18/2005CN1617855A Inhibitors of cytosolic phospholipase A2
1 ... 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 ... 573